Single doses of 300 μg/kg have been administered subcutaneously to a limited number of healthy volunteers and patients with non-small cell lung cancer without serious adverse reactions. The adverse events were similar to those in subjects receiving lower doses of pegfilgrastim.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
